Radiotherapy and concurrent chemotherapy for oesophageal carcinoma.
This retrospective non-randomized study reports the outcome of 67 patients who received radical radiotherapy with or without two courses of concomitant chemotherapy using 5-fluorouracil and cis-platin at Westmead Hospital from 1985 to 1992. The overall median survival was 14.0 months, the actuarial 5-year survival was 18%, and median disease-free survival was 11.3 months. Forty-eight per cent of the 67 patients had complete endoscopic response and this resulted in a significantly improved survival for those patients. A pretreatment baseline Karnofsky performance > or = 80, and a baseline swallowing score > or = 80 also predicted for better survival. The development of acute toxicity did not predict the likelihood of developing chronic toxicity. The incidence of stricture formation (benign and malignant) requiring dilatation was 37%. There was no significant improvement in overall or disease-free survival, nor significant worsening of toxicity in the group of patients who received concurrent radiotherapy and chemotherapy compared with patients receiving radiotherapy alone.
Hui
R
R
Division of Radiation Oncology, Westmead Hospital, NSW, Australia.
Bull
C A
CA
Gebski
V
V
O'Rourke
I
I
D000368:Aged; D000369:Aged, 80 and over; D017024:Chemotherapy, Adjuvant; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D012189:Retrospective Studies; D015996:Survival Rate